Education
About Us
Working with TipRanks
Follow Us
Bio-Path Holdings (BPTH)
:BPTH
Top Page
Bio-Path Holdings
(OTC:BPTH)
31Underperform
Bio-Path Holdings (BPTH) vs. S&P 500 (SPY)
Market Cap
$1.49M
Dividend YieldN/A
Average Volume (3M)81.72K
Price to Earnings (P/E)―
Beta (1Y)-0.89
Revenue GrowthN/A
EPS Growth79.79%
CountryUS
Employees10
SectorHealthcare
Sector Strength77
IndustryBiotechnology
Share Statistics
EPS (TTM)-7.22
Shares Outstanding8,307,892
10 Day Avg. Volume42,916
30 Day Avg. Volume81,722
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$9.00Price Target Upside4900.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bio-Path Holdings Business Overview & Revenue Model
Company DescriptionBio-Path Holdings, Inc. is a biotechnology company that develops RNAi nanoparticle drug products to treat various cancer types. The company operates within the biotechnology and pharmaceutical sectors, focusing on the development of therapeutics for cancer treatment. Its core products include pre-clinical and clinical stage candidates such as BP1001, BP1002, and BP1003, which are designed to address unmet medical needs in oncology.
How the Company Makes MoneyBio-Path Holdings makes money primarily through the development and commercialization of its proprietary drug candidates. The company's revenue model includes licensing agreements, partnerships with larger pharmaceutical firms, and potential future sales of approved drugs. Bio-Path may also receive milestone payments and royalties from these partnerships and collaborations as their drug candidates advance through clinical trials and, if successful, reach the market. Additionally, the company might engage in raising capital through stock offerings to fund its research and development efforts.
Bio-Path Holdings Financial Statement Overview
Summary
Bio-Path Holdings faces significant financial challenges, with consistent losses, negative equity, and weak cash flows. The company struggles with profitability and cash generation, which undermines its financial stability.Income Statement
Bio-Path Holdings has struggled with profitability, evident from negative gross profit and net profit margins. Despite a small revenue in the latest TTM, the company has not achieved consistent revenue growth historically. EBIT and EBITDA margins remain deeply negative, reflecting significant operational challenges.25
Negative
Balance Sheet
The balance sheet shows a negative stockholders' equity in the latest TTM, indicating financial instability. The debt-to-equity ratio is concerning due to negative equity, and the equity ratio also reflects a weak capital structure. The company faces potential risks due to high liabilities relative to its assets.20
Very Negative
Cash Flow
The cash flow statement shows persistent negative operating and free cash flow, indicating poor cash generation capability. The operating cash flow to net income ratio is unreliable due to negative values. However, the company has managed cash through financing activities, albeit unsustainably.30
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 274.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| 154.00K | -178.00K | -178.00K | -161.00K | -151.00K | -230.00K | EBIT |
| -12.40M | -15.84M | -13.90M | -10.44M | -10.91M | -8.69M | EBITDA |
| -12.27M | -15.76M | -13.69M | -10.28M | -10.73M | -8.37M | Net Income Common Stockholders |
| -10.51M | -16.08M | -13.84M | -10.44M | -10.86M | -8.51M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 1.00M | 1.05M | 10.38M | 23.77M | 13.76M | 20.43M | Total Assets |
| 2.33M | 3.22M | 15.97M | 26.57M | 16.48M | 22.66M | Total Debt |
| 0.00 | 113.00K | 221.00K | 235.00K | 330.00K | 415.00K | Net Debt |
| -1.00M | -939.00K | -10.16M | -23.54M | -13.43M | -20.01M | Total Liabilities |
| 1.12M | 2.78M | 1.80M | 1.11M | 1.41M | 1.57M | Stockholders Equity |
| 1.22M | 441.00K | 14.17M | 25.46M | 15.07M | 21.09M |
| Cash Flow | Free Cash Flow | ||||
| -9.51M | -11.54M | -15.12M | -9.99M | -10.96M | -8.36M | Operating Cash Flow |
| -9.51M | -11.54M | -15.10M | -9.92M | -10.96M | -8.36M | Investing Cash Flow |
| 0.00 | 0.00 | -21.00K | -70.00K | 0.00 | 0.00 | Financing Cash Flow |
| 7.72M | 2.20M | 1.73M | 20.01M | 4.29M | 27.78M |
Bio-Path Holdings Technical Analysis
Neutral
0.18
Price Trends
0.36
Negative
0.62
Negative
0.98
Negative
Market Momentum
-0.06
Negative
34.99
Neutral
33.60
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BPTH, the sentiment is Neutral. The current price of 0.18 is above the 20-day moving average (MA) of 0.17, below the 50-day MA of 0.36, and below the 200-day MA of 0.98, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 34.99 is Neutral, neither overbought nor oversold. The STOCH value of 33.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BPTH.
Bio-Path Holdings Risk Analysis
Bio-Path Holdings disclosed 47 risk factors in its most recent earnings report. Bio-Path Holdings reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bio-Path Holdings Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
50 Neutral | $1.52M | ― | -222.46% | ― | -16.55% | 99.28% | |
48 Neutral | $6.36B | 1.14 | -49.00% | 2.63% | 17.14% | 1.39% | |
40 Underperform | $1.10M | ― | -109.34% | ― | 0.74% | 16.31% | |
34 Underperform | $910.00K | ― | -138.34% | ― | ― | 94.78% | |
33 Underperform | $1.05M | ― | -233.77% | ― | ― | -97.16% | |
31 Underperform | $1.49M | ― | -3325.71% | ― | ― | 79.79% |
* Healthcare Sector Average
Performance Comparison
BPTH
Bio-Path Holdings
0.18
-3.71
-95.37%
WINT
Windtree Therapeutics
1.30
-367.70
-99.65%
RSLS
ReShape Lifesciences
0.46
-9.19
-95.23%
ISPC
iSpecimen
1.14
-3.06
-72.86%
ONCO
Onconetix
0.07
-6.34
-98.91%
Bio-Path Holdings Earnings Call Summary
Earnings Call Date: Mar 28, 2025 | % Change Since: 5.88% | Next Earnings Date: May 15, 2025
Earnings Call Sentiment Positive
The call highlighted significant advancements in clinical trials and the expansion of the DNAbilize platform into new therapeutic areas, reflecting strong progress in drug development. Despite some financial challenges, such as increased administrative expenses and a decrease in cash position, the overall outlook remains positive due to substantial progress in pipeline advancements and research publications.Highlights
Expansion of DNAbilize Platform
Initiation of clinical development program for BP-1001-A as a treatment for obesity and related metabolic diseases, marking the first non-cancer application of DNAbilize platform.
Progress in Cancer Treatment Trials
Continued advancement of Phase I/Ib clinical trials for BP1001-A in patients with solid tumors and BP1002 in refractory relapsed AML patients.
Publication and Potential of BP1003
Publication in Biomedicines journal highlighting the therapeutic potential of BP1003 in various cancer types, including breast, ovarian, and pancreatic cancer.
Financial Improvements
Net loss decreased to $2.1 million in Q3 2024 from $3.2 million in Q3 2023, with a decrease in research and development expenses.
Rapid Enrollment in Clinical Trials
Faster than projected enrollment for the third dosing cohort of 60 mg/m² in the BP1002 trial, completed within six weeks.
Lowlights
Increased General and Administrative Expenses
General and administrative expenses increased to $1.3 million in Q3 2024 from $1.0 million in Q3 2023, primarily due to increased legal fees and salaries.
Cash Position Decrease
Cash decreased to $0.6 million as of September 30, 2024, from $1.1 million as of December 31, 2023.
Company Guidance
In the Bio-Path Holdings Q3 2024 earnings call, the company reported a net loss of $2.1 million, or $0.70 per share, which marks an improvement from the $3.2 million loss, or $6.36 per share, in the same period last year. Research and development expenses decreased to $1.3 million from $2.3 million, attributed to reduced manufacturing costs and clinical trial expenses. General and administrative expenses rose to $1.3 million from $1.0 million, driven by increased legal fees and salaries. The company's cash reserves stood at $0.6 million as of September 30, 2024, down from $1.1 million at the end of 2023, with $7.7 million net cash used in operating activities and $7.2 million generated from financing activities over the first nine months of 2024. Bio-Path is advancing its DNAbilize platform, aiming to expand into obesity and metabolic diseases while progressing clinical trials in oncology.Bio-Path Holdings Corporate Events
Product-Related AnnouncementsBusiness Operations and Strategy
Bio-Path Holdings Reports Promising Pre-Clinical Results
Positive
Mar 19, 2025
On March 18, 2025, Bio-Path Holdings announced promising pre-clinical results for BP1001-A, indicating its potential as a treatment for obesity in Type 2 diabetes patients. The studies showed that BP1001-A attenuated fatty acid-induced insulin resistance and restored insulin sensitivity in muscle progenitor and skeletal muscle fiber cell models. This progress suggests a new application for BP1001-A beyond current weight loss drugs, potentially offering a novel therapeutic option for reducing glucose levels in patients with Type 2 diabetes. Bio-Path plans to advance these studies and file for regulatory designations to accelerate approval, with a final pre-clinical mouse model study expected in the first half of 2025 and an IND filing by year-end.
Product-Related AnnouncementsBusiness Operations and Strategy
Bio-Path Holdings Advances Clinical Pipeline for 2025
Positive
Jan 10, 2025
Bio-Path Holdings announced significant advancements in its clinical development pipeline for 2025, including the exploration of its lead product, prexigebersen, in treating both acute myeloid leukemia (AML) and obesity in Type 2 Diabetes patients. The company is focusing on utilizing molecular biomarkers to enhance patient response rates in its Phase 2 AML trial and is preparing to file an Investigational New Drug application for BP1001-A’s obesity treatment. Concurrently, Bio-Path is progressing with Phase 1/1b trials for BP1001-A and BP1002, aiming to address unmet needs in solid tumors and venetoclax-resistant AML. These developments are poised to potentially improve patient outcomes and expand Bio-Path’s market reach in oncology and metabolic disorder treatments.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.